Skip to main content

Advertisement

Table 2 Survival for patients with GBM following radiation with biological agents

From: Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients

Study Treatment Median OS Median PFS One-year survival Two-year survival
Current study (2015) (n = 73) RT + BEV + TMZ (12 cycles) 15.9 months 7.7 months 70 % 31 %
Stupp [1] (n = 287) RT + TMZ 14.6 months 6.9 months 61 % 27 %
Grossman [19] (n = 244) RT + TMZ + novel agents 19.6 months -- 81 % 37 %
Lai [21] (n = 70) RT + BEV + TMZ 19.6 months 13.6 months -- --
Vredenburgh [24] (n = 75) RT + BEV + TMZ + Irinotecan 21.2 months 14.2 months 78.7 % 44.9 %
Narayana [22] (n = 51) RT + BEV + TMZ (six cycles) 23 months 13 months 85 % 43 %
  1. OS Overall survival
  2. PFS Progression-free survival
  3. RT Radiotherapy
  4. BEV Bevacizumab
  5. TMZ Temozolomide